China's Raybow Pharmaceuticals invests $15.8 million to expand US facility
The company will triple its capacity and workforce at its North Carolina site to increase its global capabilities and reach
Raybow USA, the North American unit of China's Raybow Pharmaceuticals — a global provider of outsourced pharmaceutical process development and manufacturing services — has announced that it is tripling both its capacity and workforce at its Brevard, NC, site.
A year ago, Raybow Pharmaceuticals acquired the Brevard site through its purchase of PharmAgra Labs. The company now plans to add 74 jobs to the site's 24-strong workforce and invest $15.8 million during the next five years.
Given that Raybow USA focuses on early-stage R&D and process research through Phase II clinical trials, the new positions will include research chemists, pilot-plant personnel and supervisors.
Once the expansion is complete, the local region will benefit from a nearly $5.7 million payroll impact in the community every year, the company said.
According to Raybow Pharmaceuticals' Executive Vice President, Peter Halkjaer-Knudsen, the Brevard site will become the company's North American headquarters.
The investment will enable Raybow Pharmaceuticals, which already partners with pharmaceutical companies across Asia, Europe and North America, to increase its global capabilities and reach.
Peter Newsome, Co-President of Raybow USA said: "These investments fit perfectly with our long-term goal of expanding our operations to meet the United States."
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.